The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) announced on August 19 that their tailored mRNA cancer treatment was successful in a late-stage trial, significantly improving recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in a study of over 1,100 patients.
Details of the Trial
The Phase 3 trial, dubbed INTerpath-001, tested an individualized cancer vaccine called intismeran autogene in combination with Merck’s blockbuster immunotherapy Keytruda in patients with completely resected stage IIB-IV melanoma, meaning their visible cancer had already been surgically removed and the treatment was meant to prevent it from returning.
The trial achieved both its primary goals, recurrence-free survival, and a critical secondary target, distant metastasis-free survival, when compared to Keytruda alone. The companies stated that no new safety signals arose throughout the trial, and that the results expanded on previous Phase 2b data showing that the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone.
Why Researchers Are Calling It a Landmark
The results are significant beyond melanoma. Personalized “neoantigen” vaccines have been considered as a cancer treatment concept for many years, but this is the first randomized Phase 3 experiment to definitely confirm their effectiveness. Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology, described the results as a monumental step forward in validating mRNA technology as a cancer treatment, while Moderna Inc. (NASDAQ:MRNA) CEO Stéphane Bancel told CNN that the results were comparable in significance to the company’s November 2020 COVID-19 vaccine data, describing the event as a new chapter in cancer care.
Ripple Effects Across the Sector
Even by biotech standards, the market reacted strongly to the study results. Moderna Inc. (NASDAQ:MRNA) shares rose around 177% on the day of the news, adding approximately $45 billion to the company’s market capitalization, showing how low expectations for Moderna had gotten. Shares that had formerly traded above $400 had slipped below $30 for much of 2025, owing to slowing vaccine sales and the lack of a clear future blockbuster product. Merck & Co., Inc. (NYSE:MRK) posted a more modest but still significant 12% single-day rise.
More broadly, roughly two-thirds of health-care stocks in a broad screen of over 100 names were higher on the week, with pharmaceutical and life-sciences names such as IQVIA, Danaher, and Thermo Fisher among the sector’s other leaders, indicating that the rally is the result of renewed enthusiasm for the industry instead of a single-stock event.
Hedge Fund Sentiment
Institutional posture differed slightly between the two companies prior to the release. Moderna Inc. (NASDAQ:MRNA) saw hedge fund holdings fall somewhat, from 52 funds in the first quarter to 49 in the second quarter, which was consistent with the widely pessimistic attitude that had built up around the stock before this trial data changed the narrative. Merck & Co., Inc. (NYSE:MRK), on the other hand, saw an increase in hedge fund ownership from 98 to 101 during the same period.
The Bull Case
The case for both companies is based on clinical proof-of-concept for a technology platform with broad implications for multiple cancer types. A successful randomized Phase 3 study for a tailored neoantigen medication paves the way for extending the same strategy to additional cancers, providing both firms with a possible new, high-value therapeutic category to develop on. For Moderna Inc. (NASDAQ:MRNA), the results reflect a turnaround story for a company whose stock had plunged more than 90% from its highs due to a lack of a clear future blockbuster, and this data provides a plausible new growth channel beyond vaccines. Merck’s combo therapy increases the commercial life and addressable use of Keytruda, its largest existing franchise.
The Bear Case
That said, the therapy still needs to go through regulatory approval and commercial rollout before it can generate meaningful revenue, and personalized vaccines, which are created individually for each patient, raise cost and scalability concerns that have yet to be fully tested on a commercial scale. For Merck & Co., Inc. (NYSE:MRK), the advantage is significant but relatively smaller compared to Moderna Inc. (NASDAQ:MRNA) given the company’s size, and its slightly more moderate 12% rise implies that the market sees this as an additive rather than transformative event for a company already producing substantial revenue from Keytruda.
The Verdict
This is an instance where the clinical result appears to be substantial, indicating a first-of-its-kind validation for tailored cancer vaccines, but the scale of the market reaction likely reflects both the scientific relevance and an overall unwinding of severely low sentiment. Investors should monitor regulatory filing schedules and additional data readouts in other cancer types to determine whether this is a long-term new growth platform or a single successful study that takes years to turn into approved, revenue-generating products.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center